Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study

Archives of General Psychiatry

Volumn 60, Issue 1, 2003, Pages 92-99

  Kiefer, Falk ^a   Jahn, Holger ^a   Tarnaske, Timo ^a   Helwig, Hauke ^a   Briken, Peer ^a   Holzbach, Rüdiger ^a   Kämpf, Philipp ^a   Stracke, Robert ^b   Baehr, Michael ^a   Naber, Dieter ^a   Wiedemann, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Northern Hospital of Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; NALTREXONE; PLACEBO;

ABSTINENCE; ADULT; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRURITUS; PSYCHOTHERAPY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SELF REPORT; TREATMENT OUTCOME;

EID: 0037229412     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.60.1.92     Document Type: Article

References (55)

1. Samson HH, Harris RA. Neurobiology of alcohol abuse. Trends Pharmacol Sci. 1992;13:206-211.
2. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol. 1996;6:243-251.
3. Grant KA, Lovinger DM. Cellular and behavioral neurobiology of alcohol: receptor-mediated neuronal processes. Clin Neurosci. 1995;3:155-164.
4. Kranzler HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol. 2000;35:537-547.
5. Froehlich JC, Li TK. Opioid involvement in alcohol drinking. Ann N Y Acad Sci. 1994;739:156-167.
6. Volpicelli JR, Ulm RR, Hopson N. Alcohol drinking in rats during and following morphine injections. Alcohol. 1991;8:289-292.
7. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
8. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881-887.
9. Anton RF, Moak DH, Waid LR, Latham P, Malcolm R, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156:1758-1764.
10. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35:587-593.
11. Lee A, Tan S, Lim D, Winslow RM, Wong KE, Allen J, Hall W, Parker G. Naltrexone in the treatment of male alcoholics - an effectiveness study in Singapore. Drug Alcohol Rev. 2001;20:193-199.
12. Oslin D, Liberto JG, O'Brien J, Krois S, Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry. 1997;5:324-332.
13. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs nefazodone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology. 2000;22:493-503.
14. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96:1565-1573.
15. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res. 2001;25:1634-1647.
16. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345:1734-1739.
17. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335-1341.
18. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36:544-552.
19. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry. 1997;54:1130-1134.
20. Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, Spanagel R, Zieglgansberger W, Schadrack J. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology. 2001;40:749-760.
21. Zeise ML, Kasparov S, Capogna M, Zieglgansberger W. Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol. 1993;231:47-52.
22. Boismare F, Daoust M, Moore N, Saligaut C, Lhuintre JP, Chretien P, Durlach J. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav. 1984;21:787-789.
23. Gewiss M, Heidbreder C, Opsomer L, Durbin P, De Witte P. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol. 1991;26:129-137.
24. Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction. 1995;90:1179-1188.
25. Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, Bosimare F, Hillemand B. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet. 1985;1:1014-1016.
26. Lhuintre JP, Moore N, Tran G, Steru L, Langrenon S, Daoust M, Parot P, Ladure P, Libert C, Boismare F. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. 1990;25:613-622.
27. Pelc I, Le Bon O, Verbanck P, Lehnert PH, Opsomer L. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multi-centre study. In: Naranjo C, Sellers EM, eds. Novel Pharmacological Interventions for Alcoholism. New York, NY: Springer; 1992:348-352.
28. Ladewig D, Knecht T, Leher P, Fendl A. Acamprosate - a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch. 1993;50:182-188.
29. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239-247.
30. Roussaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics? J Pharm Belg. 1996;51:65-68.
31. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347:1438-1442.
32. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatr. 1996;53:673-680.
33. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-77.
34. Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res. 1997;3:129-137.
35. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997;92:1537-1546.
36. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22:573-579.
37. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. 2000;35:202-209.
38. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35:176-187.
39. Sass H. Results of a pooled analysis of 11 European trials comparing acamprosate and placebo on the treatment of alcohol dependence [abstract]. Alcohol Alcohol. 1995;30:484.
40. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 1997;53:1038-1053.
41. Marlatt GA, Gordon JR. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York, NY: Guilford Press; 1985.
42. Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995;19:92-99.
43. Mann K, Ackermann K. Die OCDS-G: Psychometrische Kennwerte der deutschen Version der Obsessive Compulsive Drinking Scale. Sucht. 2000;2:90-100.
44. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19:1-15.
45. Schuckit MA, Smith TL, Danko GP, Bucholz KK, Reich T, Bierut L. Five-year clinical course associated with DSM-IValcohol abuse or dependence in a large group of men and women. Am J Psychiatry. 2001;158:1084-1090.
46. Schoechlin C, Engel RR. Meta-analysis of pharmacotherapeutic trials. In: Zernig G, Saria A, Kurz M, O'Malley SS, eds. Handbook of Alcoholism. Boca Raton, Fla: CRC Press; 2000:339-352.
47. Rubio G, Jiménez-Arriero MA, Ponce G, Palomo T. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol. 2001;36:419-425.
48. Stromberg MF, Mackler SA, Volpicelli JR, O'Brien CP. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. Alcohol. 2001;23:109-116.
49. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21:287-292.
50. Swift RM. Effect of naltrexone on human alcohol consumption. J Clin Psychiatry. 1995;56(suppl 7):24-29.
51. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, Brown RA, Gulliver SB, Gordon A, Abrams DB. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res. 1999;23:1386-1394.
52. Rohsenow DJ, Monti PM. Does urge to drink predict relapse after treatment? Alcohol Res Health. 1999;23:225-232.
53. Anton RF, Kranzler HR, Meyer RE. Neurobehavioral aspects of the pharmacotherapy of alcohol dependence. Clin Neurosci. 1995;3:145-154.
54. Verheul R, van den Brink W, Geerlings PJ. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 1999;34:197-222.
55. O'Malley SS, Carroll KM. Psychotherapeutic considerations in pharmacological trials. Alcohol Clin Exp Res. 1996;20:17A-22A.